September 1, 2014

Dr. Jim Dalton began his term as Dean of the U-M College of Pharmacy on September 1, 2014, succeeding Dean Frank Ascione.

Dean Dalton is a former professor of pharmaceutical chemistry and spent time leading research and development efforts in the pharmaceutical industry.

Dean Dalton was chief scientific officer and vice president of preclinical research and development at GTx Inc., a biopharmaceutical company based in Memphis, Tennessee. Prior to his full-time commitment to GTx Inc., Dean Dalton was professor and chair of the Division of Pharmaceutics at Ohio State University.

“I am honored to become the next dean of U-M’s College of Pharmacy,” Dean Dalton said. “I’m pleased to work with our highly regarded faculty, staff and students. I am fortunate that I am following Frank Ascione as Dean. He has laid the groundwork to meet so many of the challenges coming for pharmacists and researchers. I look forward to meeting the extended College family and working closely with our alumni and friends.”

Dean Dalton earned a Bachelor of Science in pharmacy from the University of Cincinnati and a PhD in pharmaceutics and pharmaceutical chemistry from Ohio State University. He was a staff pharmacist at Kettering Medical Center in Kettering, Ohio, and had a post-doctoral fellowship in the Division of Pharmaceutics and Pharmaceutical Chemistry at OSU before starting his academic career. 

Following his fellowship he joined the Department of Pharmaceutical Sciences at the University of Tennessee as an assistant professor and was promoted to associate professor. He then joined Ohio State University College of Pharmacy faculty as an associate professor.  He served as interim chair of the Division of Pharmaceutics before being named chair of the division and being promoted to professor.

At GTx Inc., Dean Dalton oversaw all aspects of drug discovery and development, ranging from medicinal chemistry to formulation development, clinical studies, and regularly submissions.

His interdisciplinary and translational research has focused on the molecular and preclinical pharmacology of selective androgen receptor modulators (SARMs) and novel drugs in the treatment of cancer.  Dean Dalton has published more than 150 peer-reviewed scientific publications in these areas.  SARMs were first discovered in Dean Dalton’s research laboratories and he is co-inventor on hundreds of SARM patents.

Read more: U-M Pharmacy Announces New Dean Appointment